| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Androgen | 19 | 2020 | 407 | 3.100 |
Why?
|
| Prostatic Neoplasms | 19 | 2020 | 1406 | 2.470 |
Why?
|
| Phosphoric Monoester Hydrolases | 7 | 2021 | 97 | 2.030 |
Why?
|
| Receptors, Peptide | 13 | 2026 | 54 | 1.950 |
Why?
|
| Receptors, G-Protein-Coupled | 15 | 2026 | 290 | 1.820 |
Why?
|
| Relaxin | 9 | 2026 | 16 | 1.520 |
Why?
|
| Androgens | 8 | 2016 | 245 | 0.900 |
Why?
|
| Cell Proliferation | 15 | 2020 | 2461 | 0.860 |
Why?
|
| Cell Line, Tumor | 18 | 2020 | 3713 | 0.750 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 30 | 0.750 |
Why?
|
| Infertility | 1 | 2022 | 75 | 0.700 |
Why?
|
| Signal Transduction | 10 | 2021 | 4645 | 0.660 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2020 | 6 | 0.630 |
Why?
|
| Glycoside Hydrolases | 1 | 2020 | 16 | 0.630 |
Why?
|
| Natamycin | 1 | 2019 | 5 | 0.620 |
Why?
|
| DNA Ligase ATP | 1 | 2019 | 11 | 0.620 |
Why?
|
| DNA Polymerase beta | 1 | 2019 | 15 | 0.620 |
Why?
|
| DNA Repair | 2 | 2020 | 570 | 0.600 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 2010 | 0.570 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2020 | 479 | 0.570 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 104 | 0.550 |
Why?
|
| Protein Kinase C | 2 | 2018 | 113 | 0.550 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 3 | 2016 | 52 | 0.530 |
Why?
|
| Prostate | 2 | 2018 | 402 | 0.520 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2006 | 87 | 0.490 |
Why?
|
| Nuclear Receptor Coactivator 2 | 2 | 2008 | 147 | 0.480 |
Why?
|
| Transcription, Genetic | 4 | 2018 | 1364 | 0.480 |
Why?
|
| DNA-Binding Proteins | 4 | 2018 | 1932 | 0.430 |
Why?
|
| Small Molecule Libraries | 4 | 2026 | 130 | 0.420 |
Why?
|
| Disease Progression | 7 | 2016 | 2193 | 0.410 |
Why?
|
| HEK293 Cells | 7 | 2026 | 799 | 0.410 |
Why?
|
| Animals | 32 | 2026 | 33660 | 0.400 |
Why?
|
| Gene Expression | 3 | 2016 | 1479 | 0.400 |
Why?
|
| Receptors, Progesterone | 3 | 2013 | 678 | 0.400 |
Why?
|
| Testis | 4 | 2022 | 389 | 0.390 |
Why?
|
| Histone Acetyltransferases | 3 | 2009 | 226 | 0.380 |
Why?
|
| Mice | 21 | 2026 | 18153 | 0.370 |
Why?
|
| Male | 31 | 2024 | 64375 | 0.370 |
Why?
|
| Transcription Factors | 6 | 2009 | 2400 | 0.350 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 235 | 0.350 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2020 | 336 | 0.330 |
Why?
|
| Ovarian Neoplasms | 8 | 2004 | 421 | 0.320 |
Why?
|
| Spermatogenesis | 2 | 2022 | 166 | 0.320 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 2321 | 0.320 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 197 | 0.310 |
Why?
|
| Transcriptional Activation | 2 | 2012 | 418 | 0.280 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 88 | 0.280 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 106 | 0.270 |
Why?
|
| Humans | 46 | 2026 | 130071 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2011 | 1267 | 0.240 |
Why?
|
| Transfection | 7 | 2013 | 961 | 0.230 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 2329 | 0.210 |
Why?
|
| Cricetulus | 1 | 2024 | 89 | 0.210 |
Why?
|
| CHO Cells | 1 | 2024 | 151 | 0.210 |
Why?
|
| Protein Engineering | 1 | 2024 | 61 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 383 | 0.210 |
Why?
|
| Nitriles | 4 | 2016 | 161 | 0.210 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2003 | 77 | 0.190 |
Why?
|
| Anilides | 3 | 2016 | 52 | 0.190 |
Why?
|
| Inositol Phosphates | 1 | 2022 | 11 | 0.190 |
Why?
|
| Nuclear Receptor Coactivator 1 | 3 | 2009 | 161 | 0.190 |
Why?
|
| Androgen Antagonists | 3 | 2016 | 104 | 0.190 |
Why?
|
| Metribolone | 4 | 2006 | 28 | 0.190 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2020 | 248 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 371 | 0.180 |
Why?
|
| RNA, Small Interfering | 4 | 2014 | 662 | 0.180 |
Why?
|
| Semen | 1 | 2022 | 84 | 0.180 |
Why?
|
| Thymidine Kinase | 6 | 1999 | 90 | 0.180 |
Why?
|
| Androgen Receptor Antagonists | 3 | 2012 | 40 | 0.170 |
Why?
|
| Protective Agents | 1 | 2021 | 34 | 0.170 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 714 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 5 | 2008 | 1208 | 0.160 |
Why?
|
| Transcriptome | 2 | 2018 | 1102 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2009 | 757 | 0.160 |
Why?
|
| Databases, Pharmaceutical | 1 | 2019 | 6 | 0.160 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 2019 | 3 | 0.150 |
Why?
|
| Drug Synergism | 1 | 2020 | 236 | 0.150 |
Why?
|
| Tosyl Compounds | 3 | 2016 | 22 | 0.150 |
Why?
|
| Adenoviridae | 6 | 1999 | 581 | 0.140 |
Why?
|
| Genetic Therapy | 6 | 1999 | 711 | 0.140 |
Why?
|
| Cell Growth Processes | 2 | 2011 | 62 | 0.140 |
Why?
|
| Hepatic Stellate Cells | 1 | 2018 | 30 | 0.140 |
Why?
|
| COS Cells | 4 | 2012 | 253 | 0.140 |
Why?
|
| Spermatozoa | 1 | 2020 | 254 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 4690 | 0.130 |
Why?
|
| Benzamides | 1 | 2018 | 125 | 0.130 |
Why?
|
| Rats | 4 | 2026 | 3375 | 0.130 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2018 | 223 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 365 | 0.130 |
Why?
|
| Binding Sites | 4 | 2012 | 1134 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 613 | 0.130 |
Why?
|
| Gene Silencing | 2 | 2016 | 229 | 0.130 |
Why?
|
| Protein Binding | 2 | 2018 | 1649 | 0.120 |
Why?
|
| RNA Interference | 2 | 2016 | 491 | 0.120 |
Why?
|
| Cell Movement | 4 | 2014 | 874 | 0.120 |
Why?
|
| Neoplasms | 1 | 2011 | 2980 | 0.120 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 1592 | 0.110 |
Why?
|
| Cyclic AMP | 2 | 2013 | 221 | 0.110 |
Why?
|
| Liver Cirrhosis | 2 | 2019 | 901 | 0.110 |
Why?
|
| Introns | 2 | 2006 | 279 | 0.110 |
Why?
|
| Maleimides | 1 | 2014 | 10 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 378 | 0.110 |
Why?
|
| HeLa Cells | 3 | 2006 | 689 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 40 | 0.110 |
Why?
|
| High Mobility Group Proteins | 2 | 2007 | 33 | 0.110 |
Why?
|
| Chromatin | 1 | 2018 | 499 | 0.100 |
Why?
|
| p21-Activated Kinases | 1 | 2014 | 57 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 122 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 4 | 2016 | 716 | 0.100 |
Why?
|
| Receptors, Calcitriol | 2 | 2005 | 60 | 0.100 |
Why?
|
| Mice, Knockout | 2 | 2020 | 3809 | 0.100 |
Why?
|
| Models, Biological | 2 | 2011 | 1375 | 0.100 |
Why?
|
| Interleukin-8 | 1 | 2014 | 200 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 3406 | 0.100 |
Why?
|
| Receptor, ErbB-3 | 1 | 2013 | 24 | 0.100 |
Why?
|
| Mice, SCID | 1 | 2014 | 583 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 4642 | 0.100 |
Why?
|
| Indoles | 1 | 2014 | 200 | 0.100 |
Why?
|
| Apoptosis | 4 | 2020 | 1829 | 0.100 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 132 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 262 | 0.090 |
Why?
|
| Software | 1 | 2018 | 733 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 148 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 630 | 0.090 |
Why?
|
| Computational Biology | 1 | 2018 | 861 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 890 | 0.090 |
Why?
|
| Oncogenes | 1 | 2013 | 163 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2013 | 394 | 0.090 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2012 | 64 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 117 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 968 | 0.090 |
Why?
|
| Insulin | 3 | 2026 | 1143 | 0.090 |
Why?
|
| Structure-Activity Relationship | 3 | 2026 | 552 | 0.090 |
Why?
|
| Histones | 2 | 2020 | 541 | 0.080 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 448 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 426 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2020 | 951 | 0.080 |
Why?
|
| Cyproterone Acetate | 1 | 2009 | 7 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2012 | 688 | 0.070 |
Why?
|
| Butadienes | 1 | 2008 | 22 | 0.070 |
Why?
|
| Diet, High-Fat | 2 | 2021 | 268 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2009 | 284 | 0.070 |
Why?
|
| Leiomyoma | 1 | 2009 | 71 | 0.070 |
Why?
|
| RNA, Untranslated | 1 | 2009 | 109 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 125 | 0.070 |
Why?
|
| Alleles | 1 | 2013 | 1674 | 0.070 |
Why?
|
| Protein Stability | 1 | 2008 | 164 | 0.070 |
Why?
|
| Acetylation | 1 | 2008 | 191 | 0.070 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 2 | 2009 | 32 | 0.070 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2009 | 257 | 0.070 |
Why?
|
| Cytomegalovirus | 2 | 1999 | 258 | 0.060 |
Why?
|
| Ganciclovir | 2 | 1998 | 101 | 0.060 |
Why?
|
| Thymidine | 1 | 2006 | 49 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 301 | 0.060 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2008 | 264 | 0.060 |
Why?
|
| Female | 15 | 2013 | 70243 | 0.060 |
Why?
|
| Base Sequence | 2 | 2008 | 2729 | 0.060 |
Why?
|
| Cell Nucleus | 2 | 2006 | 558 | 0.060 |
Why?
|
| RNA, Long Noncoding | 1 | 2009 | 219 | 0.060 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2006 | 17 | 0.060 |
Why?
|
| Ganglia, Spinal | 1 | 2005 | 65 | 0.060 |
Why?
|
| Mice, Nude | 5 | 2010 | 699 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 69 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2004 | 140 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 147 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2006 | 108 | 0.050 |
Why?
|
| Proteins | 2 | 2026 | 1005 | 0.050 |
Why?
|
| Exons | 1 | 2006 | 759 | 0.050 |
Why?
|
| Hormones | 1 | 2004 | 162 | 0.050 |
Why?
|
| DNA Transposable Elements | 1 | 2004 | 178 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 6 | 2005 | 975 | 0.050 |
Why?
|
| Cytokines | 2 | 2020 | 1332 | 0.050 |
Why?
|
| DAX-1 Orphan Nuclear Receptor | 1 | 2003 | 7 | 0.050 |
Why?
|
| Testosterone Congeners | 1 | 2003 | 14 | 0.050 |
Why?
|
| Receptors, Interferon | 1 | 2003 | 19 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2003 | 25 | 0.050 |
Why?
|
| Hormone Antagonists | 1 | 2003 | 43 | 0.050 |
Why?
|
| Mifepristone | 1 | 2003 | 81 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2003 | 60 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2550 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 108 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2016 | 3463 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2022 | 82 | 0.050 |
Why?
|
| Avian Sarcoma Viruses | 2 | 1999 | 30 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 598 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2007 | 1588 | 0.040 |
Why?
|
| Nuclear Proteins | 2 | 2009 | 1207 | 0.040 |
Why?
|
| Antiviral Agents | 2 | 1998 | 801 | 0.040 |
Why?
|
| Mutation | 2 | 2006 | 6070 | 0.040 |
Why?
|
| Cell Line | 2 | 2018 | 2553 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2390 | 0.040 |
Why?
|
| Receptors, LH | 1 | 2020 | 14 | 0.040 |
Why?
|
| Disorders of Sex Development | 1 | 2000 | 69 | 0.040 |
Why?
|
| Meiosis | 1 | 2020 | 110 | 0.040 |
Why?
|
| Sperm Count | 1 | 2020 | 100 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2019 | 159 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2018 | 1060 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 720 | 0.040 |
Why?
|
| Drug Stability | 2 | 2013 | 56 | 0.040 |
Why?
|
| Topotecan | 1 | 1998 | 49 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2003 | 2601 | 0.030 |
Why?
|
| Acyclovir | 1 | 1998 | 49 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 330 | 0.030 |
Why?
|
| Leukocytes | 1 | 1998 | 205 | 0.030 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 1997 | 41 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 349 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2016 | 276 | 0.030 |
Why?
|
| Telomere | 1 | 1998 | 218 | 0.030 |
Why?
|
| Organoids | 1 | 2019 | 298 | 0.030 |
Why?
|
| Macaca | 1 | 2016 | 60 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1205 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2016 | 235 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2009 | 1013 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 1605 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 253 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2007 | 823 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2007 | 1481 | 0.030 |
Why?
|
| SOX9 Transcription Factor | 2 | 2007 | 83 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2013 | 84 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2013 | 96 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2013 | 71 | 0.020 |
Why?
|
| Swine | 1 | 2016 | 1184 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 222 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2013 | 364 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 331 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 136 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 409 | 0.020 |
Why?
|
| Desmin | 1 | 2009 | 19 | 0.020 |
Why?
|
| Caveolin 1 | 1 | 2009 | 51 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2009 | 54 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 929 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 647 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 1998 | 1802 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 308 | 0.020 |
Why?
|
| Adult | 3 | 2022 | 31012 | 0.020 |
Why?
|
| Leydig Cells | 1 | 2007 | 21 | 0.020 |
Why?
|
| Integrases | 1 | 2007 | 157 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 449 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 316 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 113 | 0.010 |
Why?
|
| Neoplasm Transplantation | 2 | 1997 | 358 | 0.010 |
Why?
|
| Calcium Channel Agonists | 1 | 2005 | 11 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 86 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 120 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 100 | 0.010 |
Why?
|
| Cell Survival | 2 | 1998 | 831 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 1569 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 134 | 0.010 |
Why?
|
| Calcitriol | 1 | 2005 | 63 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 304 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2884 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 411 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 480 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 238 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 242 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 718 | 0.010 |
Why?
|
| Genetic Vectors | 2 | 1999 | 892 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1803 | 0.010 |
Why?
|
| Threonine | 1 | 2002 | 62 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 2002 | 55 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 328 | 0.010 |
Why?
|
| Alanine | 1 | 2002 | 160 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 174 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2002 | 732 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2000 | 242 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 436 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2000 | 150 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 600 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 742 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1999 | 101 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2000 | 517 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 1045 | 0.010 |
Why?
|
| Testosterone | 1 | 2002 | 528 | 0.010 |
Why?
|
| Pedigree | 1 | 2000 | 1670 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 723 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 674 | 0.010 |
Why?
|
| Prognosis | 1 | 2006 | 4855 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 559 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1998 | 1214 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 12831 | 0.010 |
Why?
|
| Middle Aged | 2 | 2009 | 28305 | 0.010 |
Why?
|
| DNA | 1 | 1998 | 1398 | 0.010 |
Why?
|
| Age Factors | 1 | 1998 | 2821 | 0.010 |
Why?
|
| Phenotype | 1 | 2000 | 4461 | 0.010 |
Why?
|
| Aged | 1 | 1998 | 20818 | 0.000 |
Why?
|